JP2024516416A - 腫瘍への免疫細胞浸潤を可能にするための方法 - Google Patents

腫瘍への免疫細胞浸潤を可能にするための方法 Download PDF

Info

Publication number
JP2024516416A
JP2024516416A JP2023566662A JP2023566662A JP2024516416A JP 2024516416 A JP2024516416 A JP 2024516416A JP 2023566662 A JP2023566662 A JP 2023566662A JP 2023566662 A JP2023566662 A JP 2023566662A JP 2024516416 A JP2024516416 A JP 2024516416A
Authority
JP
Japan
Prior art keywords
cancer
subject
antigen
metastatic
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566662A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516416A5 (https=
Inventor
マリオ・フィリヨン
Original Assignee
アレシア・バイオセラピューティクス・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレシア・バイオセラピューティクス・インコーポレーテッド filed Critical アレシア・バイオセラピューティクス・インコーポレーテッド
Publication of JP2024516416A publication Critical patent/JP2024516416A/ja
Publication of JP2024516416A5 publication Critical patent/JP2024516416A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023566662A 2021-04-27 2021-04-27 腫瘍への免疫細胞浸潤を可能にするための方法 Pending JP2024516416A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2021/050572 WO2022226623A1 (en) 2021-04-27 2021-04-27 Method for allowing immune cells infiltration in tumors

Publications (2)

Publication Number Publication Date
JP2024516416A true JP2024516416A (ja) 2024-04-15
JP2024516416A5 JP2024516416A5 (https=) 2024-05-13

Family

ID=83846453

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023566662A Pending JP2024516416A (ja) 2021-04-27 2021-04-27 腫瘍への免疫細胞浸潤を可能にするための方法
JP2023565954A Pending JP2024516818A (ja) 2021-04-27 2022-04-26 腫瘍への免疫細胞浸潤を可能にするための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023565954A Pending JP2024516818A (ja) 2021-04-27 2022-04-26 腫瘍への免疫細胞浸潤を可能にするための方法

Country Status (10)

Country Link
US (2) US20240199758A1 (https=)
EP (2) EP4329801A4 (https=)
JP (2) JP2024516416A (https=)
KR (2) KR20240014052A (https=)
CN (2) CN117479955A (https=)
AU (2) AU2021442702A1 (https=)
CA (2) CA3173786A1 (https=)
IL (2) IL307954A (https=)
MX (2) MX2023012766A (https=)
WO (2) WO2022226623A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024516818A (ja) * 2021-04-27 2024-04-17 アレシア・バイオセラピューティクス・インコーポレーテッド 腫瘍への免疫細胞浸潤を可能にするための方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024009671A (es) * 2022-02-07 2024-08-19 Alethia Biotherapeutics Inc Terapia de combinación para uso en el tratamiento del cáncer de pulmón de células no pequeñas.
CN118914553B (zh) * 2024-07-22 2025-03-18 西安医学院第一附属医院 一种结直肠腺瘤和结直肠癌早期筛查的生物标志物的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013511288A (ja) * 2009-11-24 2013-04-04 アレシア・バイオセラピューティクス・インコーポレーテッド 抗クラステリン抗体及び抗原結合フラグメント並びに腫瘍容積を低減するためのそれらの使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1882A (en) 1872-12-11 Angus. Campbell A towel hanger
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
US9822170B2 (en) * 2012-02-22 2017-11-21 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
CA3173786A1 (en) * 2021-04-27 2022-10-27 Mario Filion Method for allowing immune cells infiltration in tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013511288A (ja) * 2009-11-24 2013-04-04 アレシア・バイオセラピューティクス・インコーポレーテッド 抗クラステリン抗体及び抗原結合フラグメント並びに腫瘍容積を低減するためのそれらの使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS.GOV, RETRIEVED 2021-3-26, JPN7025001961, 28 April 2020 (2020-04-28), ISSN: 0005592548 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024516818A (ja) * 2021-04-27 2024-04-17 アレシア・バイオセラピューティクス・インコーポレーテッド 腫瘍への免疫細胞浸潤を可能にするための方法

Also Published As

Publication number Publication date
AU2021442702A1 (en) 2023-11-30
KR20240013743A (ko) 2024-01-30
WO2022226637A1 (en) 2022-11-03
EP4329801A1 (en) 2024-03-06
IL307961A (en) 2023-12-01
CN117479955A (zh) 2024-01-30
CA3173786A1 (en) 2022-10-27
EP4329802A1 (en) 2024-03-06
IL307954A (en) 2023-12-01
CA3173797A1 (en) 2023-10-05
AU2022266854A9 (en) 2023-12-07
AU2022266854A1 (en) 2023-11-30
KR20240014052A (ko) 2024-01-31
EP4329802A4 (en) 2025-09-03
EP4329801A4 (en) 2025-05-14
JP2024516818A (ja) 2024-04-17
MX2023012766A (es) 2024-02-23
US20240199758A1 (en) 2024-06-20
WO2022226623A1 (en) 2022-11-03
CN117479956A (zh) 2024-01-30
US20240317884A1 (en) 2024-09-26
MX2023012768A (es) 2023-11-13

Similar Documents

Publication Publication Date Title
US12398209B2 (en) Methods of treating cancers with antagonistic anti-PD-1 antibodies
KR102679155B1 (ko) Her2 이량체화 억제제인 페르투주맙의 용도 및 이를 포함하는 제조품
JP2020524698A (ja) がんの処置における使用のためのＩＬ−１β結合性抗体
TW202233239A (zh) 用於治療非小細胞肺癌之抗b7-h1及抗ctla-4抗體
US20240317884A1 (en) Method for allowing immune cells infiltration in tumors
US20210113656A1 (en) Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment
AU2020309837A1 (en) Administration of sting agonist and checkpoint inhibitors
TW202207976A (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
JP2023011902A (ja) Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法
TW202019405A (zh) 用於治療晚期非小細胞肺癌之標靶性TGF-β抑制之組合療法
CN112118858A (zh) 用于未经治疗对象中癌症治疗的靶向tgf-β抑制的给药方案
JP2025542297A (ja) 肺癌の組み合わせ療法
US20240317854A1 (en) Methods for treating cancer with anti-ilt3 antibodies
CA2788253C (en) Combined use of pertuzumab, trastuzumab, and carboplatin for neoadjuvant therapy of early-stage her2-positive breast cancer
US20260116977A1 (en) Methods of treating melanoma using an anti-ctla4 antibody
JP2025505652A (ja) 非小細胞肺がんの治療における使用のための併用療法
WO2023164662A1 (en) Treatment of squamous non small cell lung cancer
HK40050239A (en) Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20240125

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20231027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251031

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260127